Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 201

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

HER2 Expression in Salivary Gland Carcinomas

Glisson, Bonnie, Colevas, A. Dimitrios, Haddad, Robert, Krane, Jeoffrey, El-Naggar, Adel, Kies, Merrill, Costello, Rosemary, Summey, Carmen, Arquette, Matthew, Langer, Corey, Amrein, Philip C., Posner, Marshall · 2004 · Clinical Cancer Research

Abstract

Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. As part of a Phase II trial of trastuzumab for treatment of incurable salivary gland cancer, we screened 137 tumors for HER2 expression. Experimental Design: Unstained sections of paraffin-embedded tumor samples were stained with p185/HER2 receptor antibody. Tumors with moderate (2+) to strong (3+) complete membrane staining in at least 10% of the tumor cells were scored as positive for overexpression. Results: The overall frequency of overexpression for HER2 was 17% (23 of 137), whereas it was only 8% in the three most common histological subtypes screened. Overexpression was distinctly rare in the most common subtype screened, adenoid cystic carcinoma (4%, 3 of 70). Overexpression was very common in salivary duct cancers; 10 (83%) of 12 were positive for HER2. This observation is consistent with the typical high-grade histological features and aggressive behavior of this subtype as well as with its histogenetic similarity to breast cancer. Analysis based on histogenesis (intercalated duct versus excretory duct) indicated a higher frequency of overexpression in the latter (55%) than in the former (7%). Conclusions: Our overall results suggest that trastuzumab will not have a major role in treatment of salivary gland cancers of intercalated duct origin. Further systematic evaluation of trastuzumab in subtypes of excretory duct origin could be supported.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-03-0253

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 201

Metadata

Authors
Glisson, B., Colevas, A. D., Haddad, R., Krane, J., El-Naggar, A., Kies, M., Costello, R., Summey, C., Arquette, M., Langer, C., Amrein, P. C., & Posner, M.
Venue
Clinical Cancer Research
Published
2004-02-01
Volume
10
Issue
3
Pages
944-946
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2163947995
Cited by
201
References
1
FWCI
6.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2 Expression in Salivary Gland Carcinomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0253
The paper
Glisson, B., Colevas, A. D., Haddad, R., Krane, J., El-Naggar, A., Kies, M., Costello, R., Summey, C., Arquette, M., Langer, C., Amrein, P. C., & Posner, M. (2004). HER2 Expression in Salivary Gland Carcinomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.